Pay in 4 interest-free payments of $6.34 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
pp 1026 Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG (2010) Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohns disease
Get a free no prep download here to use in your speech sessions tomorrow
The specific antisense sequences were 5-GGCUCCUACACUUCUGUUATT-3 for FoxO4 siRNA and 5-UAACAGAAGUGUAGGAGCCTT-3 for the negative control
As the third most common CV disease, VTE carries with it a substantial burden of deatharound 20%and short- and long-term complications related to both disease (e.g., recurrence, post-thrombotic syndrome) and treatment (i.e., major bleeding associated with anticoagulation treatment) [3, 4]
Ethics declarations Competing interests J.M.R has been a paid consultant to Aquestive Pharmaceuticals, Danone Nutricia, Mallinckrodt, Eisai Pharma and Zogenix, and has served on the Scientific Advisory Board of The Charlie Foundation for Ketogenic Therapies (Santa Monica, CA, USA)
US$ 29.19
US$ 20.53
US$ 29.67
US$ 26.69
US$ 26.29
US$ 21.82
